Stage-specific dual function: EZH2 regulates human erythropoiesis by eliciting histone and non-histone methylation
-
Published:2023-04-06
Issue:
Volume:
Page:
-
ISSN:1592-8721
-
Container-title:Haematologica
-
language:
-
Short-container-title:haematol
Author:
Li Mengjia,Liu Donghao,Xue Fumin,Zhang Hengchao,Yang Qianqian,Sun Lei,Qu Xiaoli,Wu Xiuyun,Zhao Huizhi,Liu Jing,Kang Qiaozhen,Wang Ting,An Xiuli,Chen Lixiang
Abstract
Enhancer of zeste homolog 2 (EZH2) is the lysine methyltransferase of polycomb repressive complex 2 (PRC2) that catalyzes H3K27 tri-methylation. Aberrant expression and loss-of-function mutations of EZH2 have been demonstrated to be tightly associated with the pathogenesis of various myeloid malignancies characterized by ineffective erythropoiesis, such as myelodysplastic syndrome (MDS). However, the function and mechanism of EZH2 in human erythropoiesis still remains largely unknown. Here, we demonstrated that EZH2 regulates human erythropoiesis in a stage-specific, dual-function manner by catalyzing histone and non-histone methylation. During the early erythropoiesis, EZH2 deficiency caused cell cycle arrest in the G1 phase, which impaired cell growth and differentiation. ChIP-seq and RNA-seq discovered that EZH2 knockdown caused a reduction of H3K27me3 and upregulation of cell cycle protein-dependent kinase inhibitors. In contrast, EZH2 deficiency led to the generation of abnormal nuclear cells and impaired enucleation during the terminal erythropoiesis. Interestingly, EZH2 deficiency downregulated the methylation of HSP70 by directly interacting with HSP70. RNA-seq analysis revealed that the expression of AURKB was significantly downregulated in response to EZH2 deficiency. Furthermore, treatment with an AURKB inhibitor and shRNA-mediated AURKB knockdown also led to nuclear malformation and decreased enucleation efficiency. These findings strongly suggest that EZH2 regulates terminal erythropoiesis through a HSP70 methylation-AURKB axis. Our findings have implications for improved understanding of ineffective erythropoiesis with EZH2 dysfunction.
Publisher
Ferrata Storti Foundation (Haematologica)